On February 8, 2023, USCAST spoke about the vision and future goals for USCAST and the 2023 in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) recommendations.

STIC were reviewed for piperacillin/tazobactam against Enterobacterales and Pseudomonas aeruginosa, various agents against A. baumannii, and aminoglycosides against Enterobacterales and P. aeruginosa. All slide presentations and Zoom videos from these presentations are now posted on the USCAST website, http://www.uscast.org/. The USCAST STIC recommendations based on these presentations are now open for public comment for the next 60 days. This open public comment period will end on April 30, 2023.

USCAST encourages all interested parties to review the presentations and to provide feedback on the content, recommendations, and process for evaluation for the topics presented via the USCAST website. Feedback that is received will be reviewed and considered prior to the finalization of STIC recommendations. They also welcome suggestions about potential pathogen/drug combinations for future evaluation. 

USCAST values your input and looks forward to hearing from you!